Home > Boards > US OTC > Medical - Drugs > Provectus Biopharmaceuticals Inc. (PVCT)
Followed By 83
Posts 11284
Boards Moderated 0
Alias Born 11/02/2003

Wednesday, March 16, 2022 9:44:28 AM

Re: None

Post# of 9821
NEWS -- Provectus Biopharmaceuticals Announces Oral Presentation of Updated Study Data from Metastatic Neuroendocrine Cancer Phase 1 Trial of PV-10® at 2022 European Neuroendocrine Tumor Society (ENETS) Annual Conference

KNOXVILLE, TN, March 16, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the treatment of neuroendocrine tumors (NET) metastatic to the liver (mNET) refractory to somatostatin analogs (SSAs) and peptide receptor radionuclide therapy (PRRT) (NCT02693067) was presented at the annual conference of the European Neuroendocrine Tumor Society (ENETS), held from March 10-11, 2022 in a hybrid setting in Barcelona, Spain and online.

The oral presentation was made by the principal investigator of the clinical trial’s single center at The Queen Elizabeth Hospital (TQEH) in Adelaide, Australia: Tim Price, MBBS, DHlthSc (Medicine), FRACP, Head of Clinical Oncology Research and Chair of the combined Hematology and Medical Oncology Unit at TQEH, and Clinical Professor in the Faculty of Medicine at the University of Adelaide.

Highlights from the 2022 ENETS Presentation:
  • Patient characteristics
    • N = 12 patients: 50% male; median age of 66 years (range 47-79)
    • Primary tumor sites: 7 small bowel (58%), 3 pancreas (25%), 1 caecal (8%), and 1 unknown (8%; likely pancreas)
    • NET grades: 5 Grade 1 (42%) and 7 Grade 2 (58%)
    • All patients were refractory to SSA (100%), and 11 received PRRT (92%) as part of their prior treatment
    • All patients had symptomatic, progressive disease
    • Baseline chromogranin A (CgA): median 1,585 µg/L (range 35-10,370)
  • PV-10 treatment
    • 4 patients (33%) received more than 1 dose (range 2-4)
    • 8 patients (67%) received 1 dose
  • Safety
    • All treatment-emergent adverse events (TEAEs) were Grade 1 or 2, primarily injection site pain (75%)
    • Single subjects experienced Grade 3 TEAEs of photosensitivity reaction or transaminases increased
  • Efficacy
    • Median progression-free survival (mPFS): 9.4 months (range 1.0-41.8)
    • Median overall survival (mOS): 22.5 months (range 5.5-42.3); 4 patients alive
    • Subgroup analysis of primary NET histology, pancreas vs intestine: mPFS 2.7 months vs 19.7 months; mOS 11.8 months vs 25.5 months
  • Quality of life (QOL)
    • Stable or improved health status and symptoms after 3 months in most patients
A recording of Dr. Price’s presentation and a copy of his slides are available on Provectus’ website at https://www.provectusbio.com/media/presentation/PV10-ENETS-2022/index.html.

Dominic Rodrigues, Vice Chair of the Company’s Board of Directors, said, “Study data continue to show encouraging local and systemic disease control, as well as symptom control, in a heavily pre-treated population and to support a role for monotherapy PV-10 as a treatment for neuroendocrine cancer patients who fail standard therapy.”

Mr. Rodrigues added, “PV-10-led combination therapies for neuroendocrine cancer patients may represent opportunities to improve quality of life and clinical outcomes. Front-line approaches may include combining liver-directed PV-10 therapy with systemically-delivered immune checkpoint inhibitors to enhance PV-10’s immune mechanisms, or using PV-10 to enhance the activity of cytotoxic treatments such as peptide receptor radionuclide therapy.”

About PV-10

Intralesional (IL) administration of PV-10 for the treatment of solid tumor cancers can yield immunogenic cell death within hours of tumor injection, and induce tumor-specific reactivity in circulating T cells within days. This PV-10-induced functional T cell response may be enhanced and boosted in combination with immune checkpoint blockade (CB). In CB-refractory disease, PV-10 may restore disease-specific T cell function. IL PV-10 has been administered to over 450 patients with melanoma and cancers of the liver in both monotherapy and combination therapy settings. IL PV-10 is administered under visual, tactile, or ultrasound guidance to superficial malignancies, and under CT or ultrasound guidance to visceral hepatic tumors.

Systemic administration of PV-10 is undergoing preclinical study as prophylactic and therapeutic treatments for high-risk and refractory adult solid tumor cancers, and as a therapeutic treatment for relapsed and refractory blood cancers.

About Provectus

Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company developing immunotherapy medicines for different disease areas based on a family of small molecules called halogenated xanthenes. Multi-route of administration drug discovery and development programs include investigational drugs and drug targets in oncology (clinical-stage), dermatology (clinical-stage), hematology, virology, microbiology, ophthalmology (clinical-stage), and animal health. Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, https://www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at https://www.provectusbio.com.


PV-10® is registered trademark of Provectus Pharmatech, Knoxville, Tennessee, U.S.A.

FORWARD-LOOKING STATEMENTS: The information in this press release may include “forward-looking statements,” within the meaning of U.S. securities legislation, relating to the business of Provectus and its affiliates, which are based on the opinions and estimates of Company management and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “project,” “predict,” “potential,” “targeting,” “intend,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.

Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.

Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the SEC, including those described in Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 and Provectus’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2021.



Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
Phone: (866) 594-5999
Recent PVCT News


Integrated Ventures Expands Its Mining Operations By Signing 5YR + 5MW Hosting Agreement With Compute North, LLC INTV Jul 6, 2022 9:00 AM

Maison Luxe Continues to Execute Its Growth Plan by Launching Luxury Sneaker E-Commerce Website: Kicks on Demand MASN Jul 6, 2022 8:39 AM

Rogue Station Companies/Everdime, Inc. Acquires Show Homes Business and Intellectual Property RGST Jul 6, 2022 8:30 AM

PSYC and Digital Acorn Ltd. Aim to Bring a First-of-its-Kind Psychedelic Hospitality-Focused Platform to Market PSYC Jul 6, 2022 8:30 AM

Unique opportunity to invest in Fast-Growing Revolutionary Marketing Software Solution for Local Businesses Jul 6, 2022 8:00 AM

Metatron Announces Deal with Health and Lifestyle Company Good Karma Global MRNJ Jul 6, 2022 6:30 AM

Kona Gold Beverage, Inc Post Record Quarterly Revenue KGKG Jul 5, 2022 9:00 AM

UAV Corp (UMAV) To build the largest lighter than air drone Hanger in the State of Florida UMAV Jul 5, 2022 8:00 AM

Pacific Booker Minerals Inc. Announces Annuals Posted and Project Update PBMLF Jul 1, 2022 9:30 AM

Maison Luxe Reports Best Ever Annual Revenues of Approximately $ 17.6 mil. for 2022 as Compared to Approximately $ 5.2 mil. for 2021, an Increase of Over 300% and Poised for Rapid Expansion in 2023 MASN Jun 30, 2022 9:58 AM

Global Fiber Technologies Secures Second Round of Inventory Financing GFTX Jun 30, 2022 9:41 AM

Sugarmade Announces Fully Executed LOI Toward Minority Stake Acquisition of Turnkey Cannabis Cultivation Property SGMD Jun 30, 2022 8:30 AM

HPIL(HPIL) Updates Shareholders HPIL Jun 30, 2022 8:30 AM

Emerging Markets Report: Cheaper. Simpler. More efficient. Ready to scale. SPYR Jun 29, 2022 11:41 AM

Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y